Efficacy and safety of oral melatonin in patients with severe COVID-19: a randomized controlled trial

Patients with COVID-19 have shown melatonin deficiency. We evaluated the efficacy and safety of administration oral melatonin in patients with COVID-19-induced pneumonia. Patients were randomly assigned in a 1:1 ratio to receive melatonin plus standard treatment or standard treatment alone. The prim...

Full description

Saved in:
Bibliographic Details
Published in:Inflammopharmacology 2023-02, Vol.31 (1), p.265-274
Main Authors: Ameri, Ali, Frouz Asadi, Masoomeh, Ziaei, Ava, Vatankhah, Majid, Safa, Omid, Kamali, Manoochehr, Fathalipour, Mohammad, Mahmoodi, Masoumeh, Hassanipour, Soheil
Format: Article
Language:English
Subjects:
Allergology
Biomedical and Life Sciences
Biomedicine
Dermatology
Gastroenterology
Immunology
Original
Original Article
Pharmacology/Toxicology
Rheumatology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with COVID-19 have shown melatonin deficiency. We evaluated the efficacy and safety of administration oral melatonin in patients with COVID-19-induced pneumonia. Patients were randomly assigned in a 1:1 ratio to receive melatonin plus standard treatment or standard treatment alone. The primary outcomes were mortality rate and requirement of IMV. The clinical status of patients was recorded at baseline and every day over hospitalization based on seven-category ordinal scale from 1 (discharged) to 7 (death). A total of 226 patients (109 in the melatonin group and 117 in the control group) were enrolled (median age; in melatonin group: 54.60 ± 11.51, in control group: 54.69 ± 13.40). The mortality rate was 67% in the melatonin group and 94% in the control group (OR; 7.75, 95% CI, 3.27–18.35, P  
ISSN:0925-4692
1568-5608
DOI:10.1007/s10787-022-01096-7